Literature DB >> 25131858

Expression of recombinant human mast cell chymase with Asn-linked glycans in glycoengineered Pichia pastoris.

Eliot T Smith1, Evan T Perry1, Megan B Sears1, David A Johnson2.   

Abstract

Recombinant human mast cell chymase (rhChymase) was expressed in secreted form as an active enzyme in the SuperMan5 strain of GlycoSwitcPichia pastoris, which is engineered to produce proteins with (Man)5(GlcNAc)2 Asn-linked glycans. Cation exchange and heparin affinity chromatography yielded 5mg of active rhChymase per liter of fermentation medium. Purified rhChymase migrated on SDS-PAGE as a single band of 30 kDa and treatment with peptide N-glycosidase F decreased this to 25 kDa, consistent with the established properties of native human chymase (hChymase). Polyclonal antibodies against hChymase detected rhChymase by Western blot. Active site titration with Eglin C, a potent chymase inhibitor, quantified the concentration of purified active enzyme. Kinetic analyses with succinyl-Ala-Ala-Pro-Phe (suc-AAPF) p-nitroanilide and thiobenzyl ester synthetic substrates showed that heparin significantly reduced KM, whereas heparin effects on kcat were minor. Pure rhChymase with Asn-linked glycans closely resembles hChymase. This bioengineering approach avoided hyperglycosylation and provides a source of active rhChymase for other studies as well as a foundation for production of recombinant enzyme with human glycosylation patterns.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chymase; Enzyme kinetics; Fermentation; Glycosylation; Pichia pastoris; Serine protease

Mesh:

Substances:

Year:  2014        PMID: 25131858      PMCID: PMC4165714          DOI: 10.1016/j.pep.2014.08.005

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  66 in total

Review 1.  Mast cell proteases: multifaceted regulators of inflammatory disease.

Authors:  Gunnar Pejler; Elin Rönnberg; Ida Waern; Sara Wernersson
Journal:  Blood       Date:  2010-03-16       Impact factor: 22.113

2.  Human enteropeptidase light chain: bioengineering of recombinants and kinetic investigations of structure and function.

Authors:  Eliot T Smith; David A Johnson
Journal:  Protein Sci       Date:  2013-03-26       Impact factor: 6.725

3.  Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic difluoromethylene ketones as novel inhibitors of human chymase.

Authors:  F Akahoshi; A Ashimori; H Sakashita; T Yoshimura; M Eda; T Imada; M Nakajima; N Mitsutomi; S Kuwahara; T Ohtsuka; C Fukaya; M Miyazaki; N Nakamura
Journal:  J Med Chem       Date:  2001-04-12       Impact factor: 7.446

4.  Secretory production of recombinant human chymase as an active form in Pichia pastoris.

Authors:  H Nakakubo; H Fukuyama; M Nakajima; T Imada; S Uno; N Shiota; S Takai; M Miyazaki; N Nakamura
Journal:  Yeast       Date:  2000-03-15       Impact factor: 3.239

5.  A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo.

Authors:  Lawrence de Garavilla; Michael N Greco; Narayanasami Sukumar; Zhi-Wei Chen; Agustin O Pineda; F Scott Mathews; Enrico Di Cera; Edward C Giardino; Grace I Wells; Barbara J Haertlein; Jack A Kauffman; Thomas W Corcoran; Claudia K Derian; Annette J Eckardt; Bruce P Damiano; Patricia Andrade-Gordon; Bruce E Maryanoff
Journal:  J Biol Chem       Date:  2005-02-28       Impact factor: 5.157

6.  Human skin chymotrypsin-like proteinase chymase. Subcellular localization to mast cell granules and interaction with heparin and other glycosaminoglycans.

Authors:  S Sayama; R V Iozzo; G S Lazarus; N M Schechter
Journal:  J Biol Chem       Date:  1987-05-15       Impact factor: 5.157

7.  Mast cell tissue inhibitor of metalloproteinase-1 is cleaved and inactivated extracellularly by alpha-chymase.

Authors:  B T Frank; J C Rossall; G H Caughey; K C Fang
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

8.  In vivo synthesis of mammalian-like, hybrid-type N-glycans in Pichia pastoris.

Authors:  Wouter Vervecken; Vladimir Kaigorodov; Nico Callewaert; Steven Geysens; Kristof De Vusser; Roland Contreras
Journal:  Appl Environ Microbiol       Date:  2004-05       Impact factor: 4.792

9.  Two distinct forms of human mast cell chymase--differences in affinity for heparin and in distribution in skin, heart, and other tissues.

Authors:  A R McEuen; M D Gaça; M G Buckley; S He; M G Gore; A F Walls
Journal:  Eur J Biochem       Date:  1998-09-01

10.  Molecular modeling study for inhibition mechanism of human chymase and its application in inhibitor design.

Authors:  Mahreen Arooj; Songmi Kim; Sugunadevi Sakkiah; Guang Ping Cao; Yuno Lee; Keun Woo Lee
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

View more
  2 in total

Review 1.  Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules.

Authors:  Isabelle Legastelois; Sophie Buffin; Isabelle Peubez; Charlotte Mignon; Régis Sodoyer; Bettina Werle
Journal:  Hum Vaccin Immunother       Date:  2016-12-01       Impact factor: 3.452

2.  Production of a recombinant peroxidase in different glyco-engineered Pichia pastoris strains: a morphological and physiological comparison.

Authors:  Alexander Pekarsky; Lukas Veiter; Vignesh Rajamanickam; Christoph Herwig; Clemens Grünwald-Gruber; Friedrich Altmann; Oliver Spadiut
Journal:  Microb Cell Fact       Date:  2018-11-24       Impact factor: 5.328

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.